RN Mobile Menu

Search form




The lack of progress in new treatments for lupus nephritis summarized in this scientific review.

(Meningitis bacteria ©EzumeImages/Shutterstock.com)

Cryptococcal meningitis infections in systemic lupus erythematosus (SLE) patients often go misdiagnosed, researchers find.

Bone with osteoperosis (©Lightspring/Shutterstock.com)

Low bone mineral density and osteoporosis are well-known comorbidities with systemic lupus erythematosus. In this slideshow, we highlight six of the most common risk factors for low bone mineral density in SLE.


Age and cumulative glucocorticoid exposure are key risk factors for low bone mineral density in systemic lupus erythematosus.


For high risk patients with systemic lupus erythematosus, teriparatide and denosumab may be an option for patients who have failed bisphosphonates. Here are some key points you need to know.


Bone loss could affect as many as 31 percent of SLE patients. This article sums up the treatment options from first-line bisphosphonate recommendations to emerging treatments like abaloparatide.


It can take as long as five years for patients presenting symptoms of systemic lupus erythematosus (SLE) to get a definitive diagnosis.


Subscribe to Lupus on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.